Multiple Phase I clinical trials are currently testing anti-TIM-3 antibodies alone or in combination with anti PD-1 therapy for the treatment of cervical and ovarian cancer and advanced recurrent solid tumors (NCT03099109, NCT02608268, NCT03652077). This evidence concerns the gene PDCD1 and ovarian carcinoma.